FY2024 Earnings Estimate for RXRX Issued By Leerink Partnrs

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) – Analysts at Leerink Partnrs reduced their FY2024 EPS estimates for Recursion Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($1.48) per share for the year, down from their previous forecast of ($1.45). The consensus estimate for Recursion Pharmaceuticals’ current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals’ Q4 2024 earnings at ($0.36) EPS and FY2025 earnings at ($1.46) EPS.

Several other research firms have also recently weighed in on RXRX. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $8.75.

Recursion Pharmaceuticals Trading Up 0.5 %

Shares of NASDAQ RXRX opened at $7.53 on Friday. The business’s 50 day moving average is $6.88 and its 200-day moving average is $6.95. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals has a 1-year low of $5.60 and a 1-year high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. During the same period in the prior year, the company earned ($0.43) earnings per share. The firm’s revenue was up 147.6% compared to the same quarter last year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $6.72, for a total value of $76,923.84. Following the transaction, the director now owns 7,077,560 shares in the company, valued at approximately $47,561,203.20. This trade represents a 0.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the sale, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. This represents a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 37,894 shares of company stock valued at $279,279 in the last ninety days. 15.75% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RXRX. Charles Schwab Investment Management Inc. boosted its stake in shares of Recursion Pharmaceuticals by 17.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock valued at $12,789,000 after purchasing an additional 288,926 shares in the last quarter. FMR LLC lifted its stake in Recursion Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company’s stock valued at $55,116,000 after purchasing an additional 170,810 shares during the last quarter. Avanza Fonder AB acquired a new stake in Recursion Pharmaceuticals in the fourth quarter valued at approximately $580,000. State Street Corp grew its stake in shares of Recursion Pharmaceuticals by 47.1% during the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after buying an additional 4,120,685 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Recursion Pharmaceuticals by 13.7% during the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after buying an additional 656,003 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.